This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giannini, R. Articles by Basolo, F. Search for Related Content PubMed PubMed Citation Articles by Giannini, R. Articles by Basolo, F. Related Collections Thyroid Endocrine Oncology

The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma

Departments of Surgery (R.G., C.U., C.L., A.P., P.B., G.M., P.M., F.B.) and Endocrinology (R.E.), University of Pisa, 56126 Pisa, Italy; and Dipartimento di Biologia e Patologia Cellulare e Molecolare (G.S., M.S.), University "Federico II", c/o Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, 80131 Naples, Italy

Address all correspondence and requests for reprints to: Fulvio Basolo, Ph.D., M.D., Department of Surgery, Division of Pathology, Via Roma, 57, 56126 Pisa, Italy. E-mail: f.basolo{at}med.unipi.it.

Context: Papillary thyroid carcinoma (PTC) is frequently multifocal. Independent PTC foci may occur either from intraglandular metastases from a single dominant tumor or as unrelated neoplastic clones. In rare cases, the simultaneous presence of PTC foci of different histopathological subtypes points to independent sites of tumor formation.

Objectives: We examined the pattern of BRAF mutations in noncontiguous tumor foci and node metastases from 69 patients affected by multicentric PTC. These included 19 cases characterized by the simultaneous presence of different PTC histopathological variants.

Design: BRAF (exon 15) mutation was examined by PCR-single strand conformational polymorphism followed by DNA sequencing in laser-capture microdissected tissue samples.

Results: Discordant patterns of BRAF mutation were found in about 40% of the multifocal PTCs. In node metastases, BRAF mutations were, in most but not all the cases, concordant with the dominant tumor. A discordant pattern of BRAF mutation was also found in about 50% of the cases in which multiple foci of different histopathological variants were present.

Conclusions: The heterogeneous distribution of BRAF mutations suggests that discrete tumor foci in multifocal PTC may occur as independent tumors. This information has to be considered in the design of targeted therapeutic approaches with BRAF pathway inhibitors.

This article has been cited by other articles:

				S. E. Baldus, K.-L. Schaefer, R. Engers, D. Hartleb, N. H. Stoecklein, and H. E. Gabbert Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases Clin. Cancer Res., February 1, 2010; 16(3): 790 - 799. [Abstract] [Full Text] [PDF]

				S. DEEN, O. L. GRIFFITH, H. MASOUDI, A. GOWN, S. J.M. JONES, and S. M. WISEMAN Anaplastic Thyroid Carcinoma Exhibits Intratumoral Molecular Homogeneity for a Therapeutic Target Panel Anticancer Res, July 1, 2009; 29(7): 2437 - 2444. [Abstract] [Full Text] [PDF]

				M. Xing, D. Clark, H. Guan, M. Ji, A. Dackiw, K. A. Carson, M. Kim, A. Tufaro, P. Ladenson, M. Zeiger, et al. BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid Cancer J. Clin. Oncol., June 20, 2009; 27(18): 2977 - 2982. [Abstract] [Full Text] [PDF]

				J. C. Ricarte-Filho, M. Ryder, D. A. Chitale, M. Rivera, A. Heguy, M. Ladanyi, M. Janakiraman, D. Solit, J. A. Knauf, R. M. Tuttle, et al. Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1 Cancer Res., June 1, 2009; 69(11): 4885 - 4893. [Abstract] [Full Text] [PDF]

				R. Elisei, C. Ugolini, D. Viola, C. Lupi, A. Biagini, R. Giannini, C. Romei, P. Miccoli, A. Pinchera, and F. Basolo BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3943 - 3949. [Abstract] [Full Text] [PDF]

				A. Antonelli, S. M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, I. Marchetti, C. Ugolini, F. Basolo, P. Miccoli, and E. Ferrannini Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration Eur. J. Endocrinol., September 1, 2008; 159(3): 283 - 291. [Abstract] [Full Text] [PDF]

				F Frasca, C Nucera, G Pellegriti, P Gangemi, M Attard, M Stella, M Loda, V Vella, C Giordano, F Trimarchi, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 191 - 205. [Abstract] [Full Text] [PDF]

				M. Xing BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications Endocr. Rev., December 1, 2007; 28(7): 742 - 762. [Abstract] [Full Text] [PDF]